563 related articles for article (PubMed ID: 11326664)
1. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
3. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
4. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
5. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
6. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
8. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
10. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
11. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
[TBL] [Abstract][Full Text] [Related]
15. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
[TBL] [Abstract][Full Text] [Related]
18. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
[TBL] [Abstract][Full Text] [Related]
19. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
20. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]